The clinical value of metabolic syndrome and risks of cardiometabolic events and mortality in the elderly: The Rotterdam study
Background: To evaluate the clinical value of metabolic syndrome based on different definitions [American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI), International Diabetes Federation (IDF) and European Group for the Study of Insulin Resistance (EGIR)] in middle-aged and elderly populations. Methods: We studied 8643 participants from the Rotterdam study (1990-2012; mean age 62.7; 57.6% female), a large prospective population-based study with predominantly elderly participants. We performed cox-proportional hazards models for different definitions, triads within definitions and each separate component for the risk of incident type 2 diabetes mellitus, coronary heart disease, stroke, cardiovascular- and all-cause mortality. Results: In our population of 8643 subjects, metabolic syndrome was highly prevalent (prevalence between 19.4 and 42.4%). Metabolic syndrome in general was associated with incident type 2 diabetes mellitus (median follow-up of 6.8years, hazard ratios 3.13-3.78). The associations with coronary heart disease (median follow-up of 7.2years, hazard ratios 1.08-1.32), stroke (median follow-up of 7.7years, hazard ratios 0.98-1.32), cardiovascular mortality (median follow-up of 8.2years, ratios 0.95-1.29) and all-cause mortality (median follow-up of 8.7years, hazard ratios 1.05-1.10) were weaker. AHA/NHLBI- and IDF-definitions showed similar associations with clinical endpoints compared to the EGIR, which was only significantly associated with incident type 2 diabetes mellitus. All significant associations disappeared after correcting metabolic syndrome for its individual components. Conclusions: Large variability exists between and within definitions of the metabolic syndrome with respect to risk of clinical events and mortality. In a relatively old population the metabolic syndrome did not show an additional predictive value on top of its individual components. So, besides as a manner of easy identification of high risk patients, the metabolic syndrome does not seem to add any predictive value for clinical practice.
|Keywords||All-cause mortality, Cardiovascular disease, Cardiovascular mortality, Diabetes mellitus, Metabolic syndrome, Preventive medicine, Rotterdam study, Stroke|
|Persistent URL||dx.doi.org/10.1186/s12933-016-0387-4, hdl.handle.net/1765/85960|
Herpt, T.T.W, Dehghan, A, van Hoek, M, Ikram, M.A, Hofman, A, Sijbrands, E.J.G, & Franco, O.H. (2016). The clinical value of metabolic syndrome and risks of cardiometabolic events and mortality in the elderly: The Rotterdam study. Cardiovascular Diabetology, 15(1). doi:10.1186/s12933-016-0387-4